RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes

Diabet Med. 2008 Aug;25(8):889-94. doi: 10.1111/j.1464-5491.2008.02514.x.


Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. Agents that either mimic GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Gastric Inhibitory Polypeptide / metabolism
  • Gastric Inhibitory Polypeptide / therapeutic use*
  • Glucagon-Like Peptide 1 / metabolism
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Humans
  • Incretins / metabolism*
  • Insulin / metabolism*
  • Insulin-Secreting Cells / metabolism*


  • Incretins
  • Insulin
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1